Unmet need
18%
On advanced therapy, not in remission
9%
Needed steroids in the first year of advanced therapy
9%
On a 3rd advanced therapy or later
10%
Primary non-response to an advanced therapy
The answers are already in the chart. CleverConsult makes them visible.
Trusted by specialists at
How CleverConsult works
Two tools built from the chart you already have
CleverConsult ingests the entire medical record from all your IBD patients and surfaces the details that matter to you and your patients.
01 · IBD Profile
One patient's story at the point of care
The patient's entire IBD history in one continuously updated summary: diagnosis, every treatment and response, labs, drug levels, endoscopy, imaging and surgeries. Every fact links back to its source document.
See a demo patient below 02 · IBD Dashboard Coming soonYour entire IBD practice in one view
Every IBD patient you follow, so you can find trends and gaps in care, patients lost to follow-up and patients who may fit a clinical trial.
See the dashboard01 · IBD Profile
For the patient in the room
The IBD Profile assembles every step of the patient's IBD journey and traces each fact back to its source document for verification.
Instantly see every endoscopy, pathology, imaging, TDM, fecal cal.
Have your patient's full history at your fingertips.
Verify each fact with citations.
Click the citation to open the source document it came from.
Effortless clinical trial screening.
Check your patient against actively recruiting clinical trials in your area.
Demo patients are synthetic. Every chart was de-identified.
Want the IBD Profile for your patients?
Tell us about your practice and we'll set it up for you.
02 · IBD Dashboard Coming soon
For your entire IBD practice
The IBD Dashboard displays a real-time view of your entire IBD practice.
See treatment journeys.
Track therapy duration, dose escalation, and discontinuation, with the documented reason for each change.
Ask any question.
Who on anti-TNF has had no TDM or fecal calprotectin in the past 12 months? Who with long-standing UC is due for surveillance colonoscopy?
Turn care gaps into call lists.
Find every patient overdue for a test or follow-up, and automatically task your admin to book it.
The full dashboard also covers care gaps, disease activity and remission, current therapy, steroid exposure and trial eligibility, and every view can be filtered by disease and drug.
Treatment sequencing
Where patients went after stopping an advanced therapy, by drug class.
| From ↓ To → | Anti-TNF | Anti-integrin | IL-12/23 inhibitor | IL-23 inhibitor | JAK inhibitor | S1P modulator |
|---|---|---|---|---|---|---|
| Anti-TNF | 24% | 17% | 19% | 24% | 16% | – |
| Anti-integrin | 38% | – | 16% | 23% | 22% | 1% |
| IL-12/23 | 28% | 24% | 1% | 32% | 14% | – |
| IL-23 | 31% | 19% | 4% | 15% | 31% | – |
| JAK | 29% | 21% | 4% | 35% | 10% | 2% |
Read across a row: of all switches away from that class, the share that went to each column. Lighter cells rest on fewer than 10 switches.
Persistence by drug class
Share of courses still on therapy at 12 months.
- Anti-TNF85%
- Anti-integrin75%
- IL-12/23 inhibitor89%
- IL-23 inhibitor91%
- JAK inhibitor83%
Persistence by therapy line
Share of courses still on therapy at 12 months.
- 1st line (no previous biologic)90%
- 2nd line or later81%
Want the IBD Dashboard for your practice?
Register your interest and we'll let you know as soon as it's live.
Clinical trial screening
Clinical trial recruitment, built into patient care
Every trial, checked automatically
Each patient is screened against every active trial's inclusion and exclusion criteria while the chart is reviewed. There is no separate chart review and nothing to set up. Only trials at your site or nearby sites are included.
Criterion by criterion
Open a trial to see which criteria the patient meets, which rule them out, and the chart evidence behind each one.
A person makes the call
Anything the chart cannot settle is flagged for review, so a coordinator confirms before the patient is approached.
Last run 2026-10-08 08:26
Needs review2
CHARGEShow ▾Hide ▴
Meets: Crohn's disease for at least 12 weeks, involving the colon, ileum or both
Ileocolonic Crohn's disease, diagnosed on colonoscopy and biopsy in May 2016.
Meets: Age ≥18 years
34 years old.
Needs review: Disease activity score (CDAI) between 220 and 450
No CDAI is recorded. The clinic note of 22 Sep 2026 describes five to six loose stools a day and daily abdominal pain for six weeks, which suggests moderate activity, but the score needs to be calculated at screening.
Meets: Active disease on endoscopy: SES-CD 6 or more, or 4 or more if only the ileum is involved
Colonoscopy 14 Jul 2026: SES-CD 9, with ulcers in the terminal ileum and ascending colon.
Needs review: No symptomatic stricture, abscess, or fistula likely to need surgery
MR enterography 2 Aug 2026 shows a 6 cm terminal ileal stricture with upstream dilation. Whether it is symptomatic needs review.
Meets: No bowel resection in the last 24 weeks
The only bowel surgery is an ileocecal resection in 2019.
Meets: No current malignancy and none in the last 5 years
No cancer history in the chart.
DUET ENCORE-CDShow ▾Hide ▴
Meets: Crohn's disease for at least 12 weeks, confirmed by endoscopy and histopathology
Diagnosed on colonoscopy and biopsy in May 2016.
Meets: Age ≥18 years
34 years old.
Needs review: Moderate to severe disease: CDAI 220 to 450, with 4 or more liquid stools a day or an abdominal pain score of 2 or more
No CDAI is recorded. The clinic note of 22 Sep 2026 describes five to six loose stools a day and daily abdominal pain for six weeks, which suggests moderate activity, but the score needs to be calculated at screening.
Meets: Moderately to severely active ileal or colonic disease on ileocolonoscopy (SES-CD)
Colonoscopy 14 Jul 2026: SES-CD 9, with ulcers in the terminal ileum and ascending colon.
Meets: Inadequate response, loss of response or intolerance to an approved systemic therapy
Loss of response to adalimumab in 2023.
Needs review: No symptomatic stricture or other complication that may need surgery
MR enterography 2 Aug 2026 shows a 6 cm terminal ileal stricture with upstream dilation. Whether it is symptomatic needs review.
Meets: No draining stoma or ostomy
No stoma in the surgical history.
Ineligible3
VICTRIVAShow ▾Hide ▴
Meets: Crohn's disease for at least 3 months, confirmed by endoscopy and histopathology
Diagnosed on colonoscopy and biopsy in May 2016.
Meets: Age 18–65 years
34 years old.
Meets: Mucosal inflammation: SES-CD 6 or more, or 4 or more if only the ileum is involved
Colonoscopy 14 Jul 2026: SES-CD 9, with ulcers in the terminal ileum and ascending colon.
Meets: Inadequate response, loss of response or intolerance to corticosteroids, immunomodulators or a biologic
Loss of response to adalimumab in 2023.
Does not meet: No infection treated with IV anti-infectives in the 30 days before baseline
IV ceftriaxone for pneumonia, 28 Sep to 3 Oct 2026.
Meets: No ostomy or ileoanal pouch
No stoma or pouch in the surgical history.
ICONIC-UCShow ▾Hide ▴
Does not meet: Ulcerative colitis for at least 12 weeks, confirmed by endoscopy and histopathology
The chart documents Crohn's disease, not ulcerative colitis.
Meets: Age ≥12 years
34 years old.
Meets: No stoma
No stoma in the surgical history.
Meets: No presence or history of a fistula
No fistula on imaging, endoscopy or examination.
Meets: No colonic resection in the last 24 weeks
The only bowel surgery is an ileocecal resection in 2019.
DUET ENCORE-UCShow ▾Hide ▴
Does not meet: Ulcerative colitis for at least 12 weeks, confirmed by endoscopy and histopathology
The chart documents Crohn's disease, not ulcerative colitis.
Does not meet: No Crohn's colitis or findings suggestive of Crohn's disease
Crohn's disease has been documented since 2016.
Meets: Age ≥18 years
34 years old.
Meets: Inadequate response, loss of response or intolerance to an approved systemic therapy
Loss of response to adalimumab in 2023.
Meets: No prior inadequate response or intolerance to guselkumab or golimumab
Neither appears in the medication history.
Why this matters
The answers are already in the chart
We know the guidelines. But the details that matter most are often buried in long charts, and patients who miss tests or appointments quietly fall behind. The published evidence shows what those gaps cost.
21%
of biologic-naïve UC patients who were overdue for follow-up had inflammation on fecal calprotectin while in clinical remission.
MacKay et al., Diseases, 2025. https://doi.org/10.3390/diseases14010002
69%
of IBD patients diagnosed with colorectal cancer had no colonoscopy in the prior 5 years.
Kim et al., Clinical Gastroenterology and Hepatology, 2022. https://doi.org/10.1016/j.cgh.2022.02.048
11% to 82%
Bone density screening rates in IBD patients before and after reminders, including an EMR prompt, made the indication visible in clinic.
Shah-Khan et al., BMJ Open Quality, 2019. https://doi.org/10.1136/bmjoq-2019-000624
Trusted by hundreds of specialists across Canada
Also included
Pre-visit charting and an AI scribe for clinic and procedure days
CleverConsult pre-drafts your note from the referral, recent visits, imaging and labs. Our GI-specific scribe completes it during the visit.
Smart document reviewer
Reads and extracts relevant data and drafts a clinical note into your customized template.
Intake forms
Patients complete a customized questionnaire and answers are seamlessly integrated into the clinical note.
Specialist scribe
With the clinical note 80% done, our specialized scribe will complete your clinical or procedure note effortlessly.
Security and integration
Built for Canadian health data
We comply with the federal and provincial health data regulations that apply to your practice, and CleverConsult works inside Accuro® through an API integration.
Privacy and Trust centre
SOC 2 Type II
Independently audited security controls.
- PHIPAOntario
- PIPEDACanada
- HIAAlberta
- HIPASaskatchewan
API integration with
Our Co-founder
What you need to know
Frequently asked questions
Does this work with my EMR?
Yes, if you use Accuro: CleverConsult works inside it through an API integration. With any other EMR, fax or upload the referral package and copy the note back into your EMR.
Is the IBD Dashboard available yet?
The IBD Dashboard is coming soon. The IBD Profile is available now.
Is this hard to implement?
No. Save your CleverConsult fax-to number in your EMR and start faxing us your referrals.
Is it PHIPA/PIPEDA compliant?
Yes. Legal and privacy are incredibly important to us. We're fully compliant with patient health information regulations and develop with security and privacy in mind.
Do I require consent from my patients to use CleverConsult?
No. CleverConsult is part of your toolset as the Health Information Custodian (HIC) and no consent is needed from patients to use it.
How do I get started?
Click "Try it free", select a time for a 15-minute onboarding meeting, and we'll see you on the virtual call at the time you selected.
Can I use templates from another scribe?
Yes. Copy and paste your templates into our template builder and you'll be set.
Do you offer a free trial?
Yes. Every account starts with a 14-day free trial, and no credit card is required.